Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Minority Interest (2018 - 2021)

Historic Minority Interest for Sangamo Therapeutics (SGMO) over the last 4 years, with Q1 2021 value amounting to -$938000.0.

  • Sangamo Therapeutics' Minority Interest fell 85645.16% to -$938000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was -$938000.0, marking a year-over-year decrease of 85645.16%. This contributed to the annual value of -$868000.0 for FY2020, which is 56918.92% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Minority Interest stood at -$938000.0 for Q1 2021, which was down 85645.16% from -$868000.0 recorded in Q4 2020.
  • Over the past 5 years, Sangamo Therapeutics' Minority Interest peaked at $739000.0 during Q4 2018, and registered a low of -$938000.0 during Q1 2021.
  • Moreover, its 4-year median value for Minority Interest was $154500.0 (2019), whereas its average is $0.0.
  • Per our database at Business Quant, Sangamo Therapeutics' Minority Interest crashed by 7496.62% in 2019 and then tumbled by 85645.16% in 2021.
  • Over the past 4 years, Sangamo Therapeutics' Minority Interest (Quarter) stood at $739000.0 in 2018, then tumbled by 74.97% to $185000.0 in 2019, then tumbled by 569.19% to -$868000.0 in 2020, then decreased by 8.06% to -$938000.0 in 2021.
  • Its Minority Interest was -$938000.0 in Q1 2021, compared to -$868000.0 in Q4 2020 and -$530000.0 in Q3 2020.